This bill requires the Food and Drug Administration to conduct a pilot program to increase the number of unannounced inspections of foreign drug manufacturing facilities and evaluate the differences between inspections of domestic and foreign facilities.
| Action Date | Type | Text | Source |
|---|---|---|---|
| 2022-03-09 | Committee | Referred to the Subcommittee on Health. | House committee actions |
| 2022-03-08 | IntroReferral | Referred to the House Committee on Energy and Commerce. | House floor actions |
| 2022-03-08 | IntroReferral | Introduced in House | Library of Congress |